Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | ubiquitin ligase sina (ec 6.3.2.-) (seven in absentia homolog)(smsina) | 0.1124 | 0.5 | 0.5 |
Echinococcus granulosus | e3 ubiquitin protein ligase siah1 | 0.1124 | 0.5 | 0.5 |
Echinococcus multilocularis | e3 ubiquitin protein ligase siah1 | 0.1124 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1124 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | > 10 % | Allosteric enhancer activity against adenosine A1 receptor | ChEMBL. | 16078833 |
Activity (binding) | > 10 % | Allosteric enhancer activity against adenosine A1 receptor | ChEMBL. | 16078833 |
Alloste ic enhan er (AE) (binding) | = 0 % | In vitro allosteric enhancer (AE) activity for adenosine A2A receptor at 50 uM | ChEMBL. | 16078833 |
Alloste ic enhan er (AE) (binding) | 0 % | In vitro allosteric enhancer (AE) activity for adenosine A1 receptor at 50 uM; ND is not determined | ChEMBL. | 16078833 |
Alloste ic enhan er (AE) (binding) | = 0 % | In vitro allosteric enhancer (AE) activity for adenosine A2A receptor at 50 uM | ChEMBL. | 16078833 |
Alloste ic enhan er (AE) (binding) | = 1 % | In vitro allosteric enhancer (AE) activity for adenosine A3 receptor at 50 uM | ChEMBL. | 16078833 |
Alloste ic enhan er (AE) (binding) | = 1 % | In vitro allosteric enhancer (AE) activity for adenosine A3 receptor at 50 uM | ChEMBL. | 16078833 |
Alloste ic enhan er (AE) (binding) | = 38 % | In vitro allosteric enhancer (AE) activity for adenosine A1 receptor at 50 uM | ChEMBL. | 16078833 |
Alloste ic enhan er (AE) (binding) | = 38 % | In vitro allosteric enhancer (AE) activity for adenosine A1 receptor at 50 uM | ChEMBL. | 16078833 |
EC50 (functional) | = 43.5 uM | Antagonist activity against adenosine A1 receptor | ChEMBL. | 16078833 |
EC50 (functional) | = 43.5 uM | Antagonist activity against adenosine A1 receptor | ChEMBL. | 16078833 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.